Kezar Life Sciences, Inc. (KZR): Price and Financial Metrics


Kezar Life Sciences, Inc. (KZR): $7.17

0.17 (+2.43%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KZR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

KZR Stock Price Chart Interactive Chart >

Price chart for KZR

KZR Price/Volume Stats

Current price $7.17 52-week high $18.55
Prev. close $7.00 52-week low $4.30
Day low $6.92 Volume 516,664
Day high $7.18 Avg. volume 665,618
50-day MA $6.99 Dividend yield N/A
200-day MA $8.12 Market Cap 490.27M

Kezar Life Sciences, Inc. (KZR) Company Bio


Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.


KZR Latest News Stream


Event/Time News Detail
Loading, please wait...

KZR Latest Social Stream


Loading social stream, please wait...

View Full KZR Social Stream

Latest KZR News From Around the Web

Below are the latest news stories about KEZAR LIFE SCIENCES INC that investors may wish to consider to help them evaluate KZR as an investment opportunity.

As The Stock Falls By -8.81% Year-To-Date, Kezar Life Sciences Inc. (NASDAQ: KZR)’S Stock Continues To Progress In 2023

During the last session, Kezar Life Sciences Inc. (NASDAQ:KZR)’s traded shares were 0.51 million, with the beta value of the company hitting 0.23. At the end of the trading day, the stock’s price was $6.42, reflecting an intraday gain of 2.72% or $0.17. The 52-week high for the KZR share is $18.55, that puts it … As The Stock Falls By -8.81% Year-To-Date, Kezar Life Sciences Inc. (NASDAQ: KZR)’S Stock Continues To Progress In 2023 Read More »

Marketing Sentinel | January 21, 2023

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., January 13, 2023--Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted two employees nonqualified stock options to purchase 65,000 shares of its common stock with an exercise price of $6.84 per share, which is equal to the closing price of Kezar’s common

Yahoo | January 13, 2023

Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated

Business Wire | January 4, 2023

Kezar Life Sciences Inc. (NASDAQ: KZR) Shares Are Set To Rise By 2022

Kezar Life Sciences Inc. (NASDAQ:KZR) shares, rose in value on Friday, 12/30/22, with the stock price up by 0.14% to the previous day’s close as strong demand from buyers drove the stock to $7.04. Actively observing the price movement in the last trading, the stock closed the session at $7.03, falling within a range of … Kezar Life Sciences Inc. (NASDAQ: KZR) Shares Are Set To Rise By 2022 Read More »

Stocks Register | December 31, 2022

Have you been able to find a good deal on Kezar Life Sciences Inc.’s shares?

As of Thursday, Kezar Life Sciences Inc.’s (NASDAQ:KZR) stock closed at $7.03, up from $6.60 the previous day. While Kezar Life Sciences Inc. has overperformed by 6.52%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KZR fell by -56.95%, with highs and lows ranging from $18.55 […]

US Post News | December 30, 2022

Read More 'KZR' Stories Here

KZR Price Returns

1-mo 1.85%
3-mo -2.58%
6-mo -28.30%
1-year -45.60%
3-year 133.55%
5-year N/A
YTD 1.85%
2022 -57.89%
2021 220.31%
2020 30.17%
2019 -83.01%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6326 seconds.